Jeffrey Arnoult, MD
Ophthalmology · Houston, TXNPI 1396730065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Alcon at 31.7% of the total. Reporting peaked in 2019 at $1,701 and has fallen 55.6% since, to $755 in 2025.
Across 260 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$2K
- Novartis$620
- Bausch & Lomb Americas Inc.$337
- Eyevance Pharmaceuticals LLC$306
- Kala Pharmaceuticals, Inc.$225
- plus $983 from 15 others
Across 16 payments — averaging $1270.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$17K
- Glaukos Corporation$4K
What the payments were for
- Food & beverage$5,951100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 53 | $1,884 |
| AbbVie(2 entities) | 77 | $1,597 |
| Novartis | 38 | $620 |
| Bausch & Lomb Americas Inc. | 17 | $337 |
| Eyevance Pharmaceuticals LLC | 20 | $306 |
| Kala Pharmaceuticals, Inc. | 11 | $225 |
| Sun Pharmaceutical Industries Inc. | 9 | $180 |
| Oyster Point Pharma, Inc. | 7 | $166 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $143 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $99 |
| Thea Pharma Inc. | 3 | $68 |
| Ocular Therapeutix, Inc. | 4 | $67 |
| Aerie Pharmaceuticals, Inc. | 3 | $61 |
| Ivantis, Inc | 1 | $47 |
| Shire North American Group Inc | 2 | $45 |
| Akorn, Inc. | 2 | $34 |
| Harrow Eye, LLC | 1 | $25 |
| Glaukos Corporation | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $14 |
| Akorn Operating Company LLC | 1 | $12 |
| Rxsight Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$269
- PanOptix$150
- Clareon PanOptix Pro$148
- ReSTOR$141
- Tecnis Multifocal Family of 1-piece IOLS$120
- LUMIGAN$120
How this compares
$5,951 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 727 | $296,507 |
| CombiganBrimonidine Tartrate/Timolol | 286 | $91,681 |
| RestasisCyclosporine | 73 | $86,057 |
| VyzultaLatanoprostene Bunod | 91 | $40,994 |
| XiidraLifitegrast | 32 | $28,120 |
| Travoprost | 119 | $17,646 |
| Latanoprost | 1,894 | $17,076 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 131 | $14,275 |
| ProlensaBromfenac Sodium | 41 | $13,908 |
| Lotemax SmLoteprednol Etabonate | 55 | $13,533 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 745 | $12,983 |
| RhopressaNetarsudil Mesylate | 30 | $12,285 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $11,331 |
| Alphagan PBrimonidine Tartrate | 32 | $9,451 |
| Acetazolamide ErAcetazolamide | 270 | $8,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,597 | $483,6961,118 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $337 | $69,113123 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $99 | $27,44196 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $61 | $23,61660 claims |
| Eyevance Pharmaceuticals LLCFlarex | $306 | $5,96849 claims |
| AlconSimbrinza | $1,884 | $2,32311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.